Clin2
NCT07174947Possibly a fitRecruiting

Fluoxetine plus immunotherapy for advanced liver cancer with depression

Hepatobiliary MalignancyFluoxetineAnxiety DisordersDepression Disorders

Treatments studied

Part of Mental health clinical trials.

This study tests whether adding the antidepressant fluoxetine (Prozac) to standard immunotherapy can help treat advanced liver or bile duct cancer in people who also have depression or anxiety. You must not have received any prior cancer treatment and be ready to start immunotherapy as your first therapy.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
240 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You have advanced liver or bile duct cancer (hepatocellular carcinoma or cholangiocarcinoma) that has spread or can't be removed with surgery.
  • You haven't had any cancer treatment yet, and your doctor plans to start you on immunotherapy (a type of drug that helps your immune system fight cancer).
  • You feel down or anxious most of the time, with a score that suggests depression or anxiety on a standard screening questionnaire (PHQ-9 or GAD-7).
  • You are able to swallow pills.
  • Your blood counts and liver/kidney function tests are within certain safe limits (your doctor will check these).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07836712Not yet recruiting· Phase 2
Extra treatments to boost immunotherapy for advanced melanoma or liver cancer

This study tests additional therapies given alongside standard immunotherapy for advanced melanoma or liver cancer. The goal is to see if adding these treatments can make the immunotherapy work better.

Los Angeles, California
NCT06708650Not yet recruiting
Radiation plus immunotherapy for advanced liver cancer

This trial tests a combination of liver-directed radiation therapy, an immunotherapy drug (which helps your immune system fight cancer), and a drug that blocks blood vessel growth to the tumor. It is for people with advanced liver cancer that cannot be treated with surgery.

Guiping, Guangxi
NCT07522411Not yet recruiting· Phase 1/Phase 2
Combination therapy before surgery for high-risk liver cancer

This trial tests whether giving a combination of chemotherapy, immunotherapy, and targeted therapy before surgery can shrink liver cancer and reduce the chance of it coming back, compared to going straight to surgery. The treatment includes medicines like pembrolizumab (sintilimab) and a drug that blocks blood vessel growth (bevacizumab).

NCT06172205Recruiting· Phase 3
Two ways to give chemo plus immunotherapy for advanced liver cancer

This study tests whether a combination of chemotherapy (FOLFOX) plus two immunotherapy drugs (Camrelizumab and Apatinib) works better when given directly into the liver artery (HAIC) versus through a vein. It's for people with advanced liver cancer who haven't had other treatments yet.

Guangzhou, Guangdong
NCT06999707Recruiting· Phase 2
Radiation plus immunotherapy for advanced liver cancer

This trial tests a combination of targeted radiation (photon radiotherapy) with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer that can't be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.

Taoyuan City, Taiwan
NCT07835737Not yet recruiting· Phase 1/Phase 2
Folic acid with standard immunotherapy for liver cancer

This trial tests whether adding folic acid to the usual first-line treatment (two drugs called atezolizumab and bevacizumab) is safe and works better for people with advanced liver cancer that cannot be surgically removed. It may help your body fight the cancer while controlling bleeding risks.

Hear when a new Anxiety Disorders trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.